Programs advancing across obesity, immunology, and rare disease — with strategic partners including ProGen Co., Ltd. and Chugai Pharmaceutical.
| Program | Target / Molecule | Indication | Phase | Partner |
|---|---|---|---|---|
| RT-114 | GLP-1/GLP-2 | Obesity | Phase 2 | ProGen Co., Ltd. |
| RT-116 | Semaglutide | Obesity | Phase 1 | — |
| RT-105 | Adalimumab Biosimilar | Psoriatic Arthritis | Phase 1 | — |
| RT-111 | Ustekinumab Biosimilar | Psoriasis | Phase 1 | — |
| RT-117 | Undisclosed | Rare Disease | Discovery | Chugai Pharmaceutical |
* Clinical timelines are subject to potential regulatory agency review delays
** RT-114 is the subject of a worldwide collaboration with ProGen Co, Ltd.
*** Ustekinumab and adalimumab biosimilars are supplied by Celltrion, Inc. Celltrion grants Rani a license and drug supply for each drug.
**** RT-117 is the subject of a worldwide collaboration and license with Chugai Pharmaceutical Co., Ltd.
The Rani platform is capable of delivering orally any payload across a wide range of therapeutic areas.